JMJD3 CRISPR/Cas9 KO Plasmid (h2): sc-401883-KO-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- JMJD3 CRISPR/Cas9 Knockout (KO) Plasmid (h2) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the JMJD3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JMJD3 CRISPR/Cas9 KO Plasmid (h2) | sc-401883-KO-2 | 20 µg | $397.00 |
Overview
KDM6B encodes the histone demethylase JMJD3, a Fe(II)/2-oxoglutarate–dependent dioxygenase that removes repressive H3K27me3 marks to promote transcriptional activation. Through epigenetic remodeling, JMJD3 influences developmental gene programs, cell fate transitions, senescence, and stimulus-responsive transcription downstream of pathways such as NF-κB and TGF-β/SMAD. Its activity shapes chromatin accessibility at lineage-specific enhancers and promoters, contributing to regulation of inflammation and differentiation across multiple cell types. Dysregulated KDM6B/JMJD3 function has been implicated in cancer epigenetics, immune-mediated disease biology, and other contexts where aberrant chromatin states alter gene expression networks.
JMJD3 CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the KDM6B gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KDM6B together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KDM6B open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish JMJD3 protein expression.
This CRISPR knockout system enables efficient generation of KDM6B-deficient cell models for investigation of JMJD3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KDM6B exon(s) critical for JMJD3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KDM6B genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by JMJD3 CRISPR/Cas9 KO Plasmid (h) and JMJD3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KDM6B locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by JMJD3 HDR Plasmid (h) and JMJD3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KDM6B homology arms to support homology-directed repair at defined KDM6B target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.